ALTERITY THERAPEUTICS LIMITED - Announcements

6.67%

1.4¢

Market Cap $128.9M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATH	Prana Commences Alzheimer's Trial Recruitment		15/12/11	241.34KB	Share
ATH	Results of 2011 Annual General Meeting		29/11/11	26.82KB	Share
ATH	Key Patent for Parkinson's Drug PBT434 Secured in USA	PRICE SENSITIVE	28/11/11	28.6KB	Share
ATH	Appendix 3B and Section 708A Notice		25/11/11	100.32KB	Share
ATH	Prana Receives Approval For Alzheimer's Trial	PRICE SENSITIVE	22/11/11	332.05KB	Share
ATH	Appendix 3B and Section 708A Notice		21/11/11	100.28KB	Share
ATH	PBT2 reverses the loss of synaptic activity in neurons	PRICE SENSITIVE	14/11/11	181.51KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		28/10/11	110.28KB	Share
ATH	Australian Government funds study into benefits of PBT2	PRICE SENSITIVE	27/10/11	186.36KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/11	59.1KB	Share
ATH	Government Grant to Study effect of PBT2 in the ageing brain	PRICE SENSITIVE	20/10/11	231.52KB	Share
ATH	Results of 2011 General Meeting		07/10/11	43.58KB	Share
ATH	Form 20-F		03/10/11	663.78KB	Share
ATH	Annual Report 2011		23/09/11	2.54MB	Share
ATH	Appendix 3B and Section 708A Notice		22/09/11	100.95KB	Share
ATH	Appendix 3B and Section 708A Notice		21/09/11	101.15KB	Share
ATH	Appendix 3B and Section 708A Notice		19/09/11	101.22KB	Share
ATH	Prana's PBT2 Directly Restores Neurons Critical to Cognition	PRICE SENSITIVE	19/09/11	52.57KB	Share
ATH	Planned Huntington's trial receives strong interest		16/09/11	48.14KB	Share
ATH	World Congress on Huntington's learns about PBT2's Promise		14/09/11	50.26KB	Share
ATH	Trial presented at World Congress on Huntington's Disease	PRICE SENSITIVE	12/09/11	48.23KB	Share
ATH	Notice of General Meeting/Proxy Form		06/09/11	110.67KB	Share
ATH	Appendix 4E - Preliminary Financial Report	PRICE SENSITIVE	25/08/11	121.23KB	Share
ATH	Prana Receives Michael J. Fox Foundation Grant	PRICE SENSITIVE	22/08/11	52.17KB	Share
ATH	Ceasing to be a substantial holder		19/08/11	17.01KB	Share
ATH	Appendix 3X - LG		09/08/11	42.54KB	Share
ATH	Leading Investor Lawrence Gozlan Joins Board of Directors		08/08/11	83.2KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/11	59.46KB	Share
ATH	PBT2 presented in a Plenary Lecture at ICAD in Paris		21/07/11	94.69KB	Share
ATH	Prospectus Supplement	PRICE SENSITIVE	14/07/11	194.94KB	Share
ATH	Form 6-K		14/07/11	190.15KB	Share
ATH	Prana Announces At-the-Market Issuance Program	PRICE SENSITIVE	14/07/11	45.27KB	Share
ATH	Change in substantial holding		04/07/11	389.76KB	Share
ATH	Change in substantial holding		01/07/11	26.14KB	Share
ATH	Appendix 3B and Section 708A Notice		01/07/11	103.24KB	Share
ATH	Quintiles Makes Second Investment in Prana	PRICE SENSITIVE	30/06/11	44.17KB	Share
ATH	Prana's PBT2 presented at HDSA National Convention		28/06/11	49.45KB	Share
ATH	Results of 2011 General Meeting		10/06/11	40.4KB	Share
ATH	Prana's Scientists Present Findings World Pharma Congress		08/06/11	64.77KB	Share
ATH	Form F-3		18/05/11	337.2KB	Share
ATH	Notice of General Meeting/Proxy Form		12/05/11	130.95KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/11	59.45KB	Share
ATH	Prana accelerates PBT2 commercial development	PRICE SENSITIVE	20/04/11	79.77KB	Share
ATH	Prana secures key PBT2 patent in Japan	PRICE SENSITIVE	11/04/11	80.12KB	Share
ATH	Form F-3 - Registration Statement		11/04/11	120.68KB	Share
ATH	Appendix 3B and Section 708A Notice		08/04/11	101.56KB	Share
ATH	Form 6-K		01/04/11	129.92KB	Share
ATH	Prana's PBT2 Phase II trial receives funding from ADDF	PRICE SENSITIVE	31/03/11	60.35KB	Share
ATH	Form 6-K - Placement		25/03/11	146.36KB	Share
ATH	Prana Raises A$6.19 million in a Private Placement	PRICE SENSITIVE	23/03/11	45.27KB	Share
ATH	PBT2 - Directly Restores Neurons Critical to Cognition	PRICE SENSITIVE	21/03/11	49.32KB	Share
ATH	Lead Parkinsons Drug Presented at International Conference		15/03/11	48.85KB	Share
ATH	Prana to Present at Cowen and Company Health Care Conference		09/03/11	42.85KB	Share
ATH	Appendix 3B and Section 708A Notice		04/03/11	100.6KB	Share
ATH	Prana's Co-Founding Scientist Awarded Prestigious Fellowship	PRICE SENSITIVE	04/03/11	45.58KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	01/03/11	1.1MB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	18/02/11	136.68KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/11	71.46KB	Share
ATH	Appendix 3Z - Paul Marks		04/01/11	55.21KB	Share
ATH	Resignation of Non-executive Director		04/01/11	31.5KB	Share
ATH	Appendix 3Y - Paul Marks		03/12/10	52.8KB	Share
ATH	Results of 2010 Annual General Meeting		26/11/10	25.89KB	Share
ATH	Broadcast on plans to advance Alzheimers Clinical Trial		11/11/10	29.4KB	Share
ATH	Form 20-F		10/11/10	1.5MB	Share
ATH	Prana plans to advance Alzheimers clinical trial	PRICE SENSITIVE	08/11/10	26.08KB	Share
ATH	Trading Halt	PRICE SENSITIVE	04/11/10	49.84KB	Share
ATH	Trading Halt Request		04/11/10	52.15KB	Share
ATH	Appendix 3B and Section 708A Notice		04/11/10	107.61KB	Share
ATH	Appendix 3Y - GK, GM, BM, PM, PM		03/11/10	167.48KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/10	62.01KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		22/10/10	71.58KB	Share
ATH	Appendix 3B and Section 708A Notice		08/10/10	138.19KB	Share
ATH	Annual Report to shareholders		30/09/10	2.17MB	Share
ATH	Prana selects lead PD drug candidate for development	PRICE SENSITIVE	29/09/10	31.93KB	Share
ATH	Appendix 3B		27/09/10	123.66KB	Share
ATH	Cell publishes critical role of metals in Alzheimers Disease		03/09/10	34.3KB	Share
ATH	Appendix 4E for the Year Ended 30 June 2010	PRICE SENSITIVE	27/08/10	242.15KB	Share
ATH	Prana secures key PBT2 patents in the US and Europe	PRICE SENSITIVE	24/08/10	31.44KB	Share
ATH	Results of General Meeting		17/08/10	30.98KB	Share
ATH	Prana Cited in New Scientist Magazine Article		03/08/10	30.69KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/10	65.91KB	Share
ATH	Appendix 3B and Section 708A Notice		19/07/10	123.38KB	Share
ATH	Pranas Research Presented at Alzheimers Disease Conference		19/07/10	75.56KB	Share
ATH	Notice of General Meeting/Proxy Form		19/07/10	67.78KB	Share
ATH	New PBT2 data in 2010 Hot Topics Session	PRICE SENSITIVE	01/07/10	82.71KB	Share
ATH	Investment by Quintiles, Placement of 225 million Shares	PRICE SENSITIVE	28/06/10	31.25KB	Share
ATH	Review of the Role of Metals in Alzheimers Disease		21/06/10	30.95KB	Share
ATH	Appendix 3B and Section 708A Notice		08/06/10	124.66KB	Share
ATH	Prana to Present Findings at American Aging Assoc Meeting		01/06/10	30.35KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/10	75.25KB	Share
ATH	Prana Provides Analysis of PBT2 Therapeutic Strategy for AD	PRICE SENSITIVE	29/04/10	31.44KB	Share
ATH	Ceasing to be a substantial holder		23/04/10	206.13KB	Share
ATH	Prana to commence Phase 11b trial on PBT2	PRICE SENSITIVE	20/04/10	31.12KB	Share
ATH	New Analysis of Clinical Trial published in Journal of AD	PRICE SENSITIVE	19/04/10	42.64KB	Share
ATH	Change in substantial holding		05/03/10	217.32KB	Share
TSN +ACR ADU AED AEJ AEZ AIO AJA RCM AMU ATM AVG AVX AXM AZZ ASQ BCS BLY BUL CAA CAH CBH CCP CDI PRG CIX CMV COK COZ CPL CRE CSV CTO CUV CVC CWT CXC CXM DCG DKN DLS DML DOM EAU EPX FEA FGE FML FPG FRS GDO ETM GPM GWR GXY GZL HDI NGI HGO HIG HIN HTA IDT ILF IMD IOH ITO IVA KAM KMD KRL KRM LLA MAE AEV MCE MCP MDT MEL MFG MIN 5GN GG8 MMW MRE MSF MTU MYR MYS NAN NBS NEC DTZ NGE NGF NKP NOD KZA NVT OAK OEL SYN AKE PBP ATH PME PPI PRU PTN AX1 RCI RCT VAU REF RFE RRL RXM SAR SFC SFH SFR SGN SGT SLR SNO SPL SRV SSM SUL TAM TCQ TGA TOX TPM TZL UBI UNS VIR VMG VPE VRL VTA WDS WEC WTP WYL ZSP	SandP Announces March SP/ASX Index Rebalance		05/03/10	35.82KB	Share
ATH	Appendix 3B and Section 708A Notice		02/03/10	107.66KB	Share
ATH	Ceasing to be a substantial holder		01/03/10	489.95KB	Share
ATH	Form 6-K		26/02/10	98.94KB	Share
ATH	Appendix 4D for the Half Year Ended 31 December 2009	PRICE SENSITIVE	25/02/10	1.04MB	Share

ATHPrana Commences Alzheimer's Trial Recruitment
15/12/11		241.34KB	Share
ATHResults of 2011 Annual General Meeting
29/11/11		26.82KB	Share
ATHKey Patent for Parkinson's Drug PBT434 Secured in USA
28/11/11	PRICE SENSITIVE	28.6KB	Share
ATHAppendix 3B and Section 708A Notice
25/11/11		100.32KB	Share
ATHPrana Receives Approval For Alzheimer's Trial
22/11/11	PRICE SENSITIVE	332.05KB	Share
ATHAppendix 3B and Section 708A Notice
21/11/11		100.28KB	Share
ATHPBT2 reverses the loss of synaptic activity in neurons
14/11/11	PRICE SENSITIVE	181.51KB	Share
ATHNotice of Annual General Meeting/Proxy Form
28/10/11		110.28KB	Share
ATHAustralian Government funds study into benefits of PBT2
27/10/11	PRICE SENSITIVE	186.36KB	Share
ATHAppendix 4C - quarterly
27/10/11	PRICE SENSITIVE	59.1KB	Share
ATHGovernment Grant to Study effect of PBT2 in the ageing brain
20/10/11	PRICE SENSITIVE	231.52KB	Share
ATHResults of 2011 General Meeting
07/10/11		43.58KB	Share
ATHForm 20-F
03/10/11		663.78KB	Share
ATHAnnual Report 2011
23/09/11		2.54MB	Share
ATHAppendix 3B and Section 708A Notice
22/09/11		100.95KB	Share
ATHAppendix 3B and Section 708A Notice
21/09/11		101.15KB	Share
ATHAppendix 3B and Section 708A Notice
19/09/11		101.22KB	Share
ATHPrana's PBT2 Directly Restores Neurons Critical to Cognition
19/09/11	PRICE SENSITIVE	52.57KB	Share
ATHPlanned Huntington's trial receives strong interest
16/09/11		48.14KB	Share
ATHWorld Congress on Huntington's learns about PBT2's Promise
14/09/11		50.26KB	Share
ATHTrial presented at World Congress on Huntington's Disease
12/09/11	PRICE SENSITIVE	48.23KB	Share
ATHNotice of General Meeting/Proxy Form
06/09/11		110.67KB	Share
ATHAppendix 4E - Preliminary Financial Report
25/08/11	PRICE SENSITIVE	121.23KB	Share
ATHPrana Receives Michael J. Fox Foundation Grant
22/08/11	PRICE SENSITIVE	52.17KB	Share
ATHCeasing to be a substantial holder
19/08/11		17.01KB	Share
ATHAppendix 3X - LG
09/08/11		42.54KB	Share
ATHLeading Investor Lawrence Gozlan Joins Board of Directors
08/08/11		83.2KB	Share
ATHAppendix 4C - quarterly
27/07/11	PRICE SENSITIVE	59.46KB	Share
ATHPBT2 presented in a Plenary Lecture at ICAD in Paris
21/07/11		94.69KB	Share
ATHProspectus Supplement
14/07/11	PRICE SENSITIVE	194.94KB	Share
ATHForm 6-K
14/07/11		190.15KB	Share
ATHPrana Announces At-the-Market Issuance Program
14/07/11	PRICE SENSITIVE	45.27KB	Share
ATHChange in substantial holding
04/07/11		389.76KB	Share
ATHChange in substantial holding
01/07/11		26.14KB	Share
ATHAppendix 3B and Section 708A Notice
01/07/11		103.24KB	Share
ATHQuintiles Makes Second Investment in Prana
30/06/11	PRICE SENSITIVE	44.17KB	Share
ATHPrana's PBT2 presented at HDSA National Convention
28/06/11		49.45KB	Share
ATHResults of 2011 General Meeting
10/06/11		40.4KB	Share
ATHPrana's Scientists Present Findings World Pharma Congress
08/06/11		64.77KB	Share
ATHForm F-3
18/05/11		337.2KB	Share
ATHNotice of General Meeting/Proxy Form
12/05/11		130.95KB	Share
ATHAppendix 4C - quarterly
28/04/11	PRICE SENSITIVE	59.45KB	Share
ATHPrana accelerates PBT2 commercial development
20/04/11	PRICE SENSITIVE	79.77KB	Share
ATHPrana secures key PBT2 patent in Japan
11/04/11	PRICE SENSITIVE	80.12KB	Share
ATHForm F-3 - Registration Statement
11/04/11		120.68KB	Share
ATHAppendix 3B and Section 708A Notice
08/04/11		101.56KB	Share
ATHForm 6-K
01/04/11		129.92KB	Share
ATHPrana's PBT2 Phase II trial receives funding from ADDF
31/03/11	PRICE SENSITIVE	60.35KB	Share
ATHForm 6-K - Placement
25/03/11		146.36KB	Share
ATHPrana Raises A$6.19 million in a Private Placement
23/03/11	PRICE SENSITIVE	45.27KB	Share
ATHPBT2 - Directly Restores Neurons Critical to Cognition
21/03/11	PRICE SENSITIVE	49.32KB	Share
ATHLead Parkinsons Drug Presented at International Conference
15/03/11		48.85KB	Share
ATHPrana to Present at Cowen and Company Health Care Conference
09/03/11		42.85KB	Share
ATHAppendix 3B and Section 708A Notice
04/03/11		100.6KB	Share
ATHPrana's Co-Founding Scientist Awarded Prestigious Fellowship
04/03/11	PRICE SENSITIVE	45.58KB	Share
ATHHalf Yearly Report and Accounts
01/03/11	PRICE SENSITIVE	1.1MB	Share
ATHResponse to ASX Price Query
18/02/11	PRICE SENSITIVE	136.68KB	Share
ATHAppendix 4C - quarterly
28/01/11	PRICE SENSITIVE	71.46KB	Share
ATHAppendix 3Z - Paul Marks
04/01/11		55.21KB	Share
ATHResignation of Non-executive Director
04/01/11		31.5KB	Share
ATHAppendix 3Y - Paul Marks
03/12/10		52.8KB	Share
ATHResults of 2010 Annual General Meeting
26/11/10		25.89KB	Share
ATHBroadcast on plans to advance Alzheimers Clinical Trial
11/11/10		29.4KB	Share
ATHForm 20-F
10/11/10		1.5MB	Share
ATHPrana plans to advance Alzheimers clinical trial
08/11/10	PRICE SENSITIVE	26.08KB	Share
ATHTrading Halt
04/11/10	PRICE SENSITIVE	49.84KB	Share
ATHTrading Halt Request
04/11/10		52.15KB	Share
ATHAppendix 3B and Section 708A Notice
04/11/10		107.61KB	Share
ATHAppendix 3Y - GK, GM, BM, PM, PM
03/11/10		167.48KB	Share
ATHAppendix 4C - quarterly
27/10/10	PRICE SENSITIVE	62.01KB	Share
ATHNotice of Annual General Meeting/Proxy Form
22/10/10		71.58KB	Share
ATHAppendix 3B and Section 708A Notice
08/10/10		138.19KB	Share
ATHAnnual Report to shareholders
30/09/10		2.17MB	Share
ATHPrana selects lead PD drug candidate for development
29/09/10	PRICE SENSITIVE	31.93KB	Share
ATHAppendix 3B
27/09/10		123.66KB	Share
ATHCell publishes critical role of metals in Alzheimers Disease
03/09/10		34.3KB	Share
ATHAppendix 4E for the Year Ended 30 June 2010
27/08/10	PRICE SENSITIVE	242.15KB	Share
ATHPrana secures key PBT2 patents in the US and Europe
24/08/10	PRICE SENSITIVE	31.44KB	Share
ATHResults of General Meeting
17/08/10		30.98KB	Share
ATHPrana Cited in New Scientist Magazine Article
03/08/10		30.69KB	Share
ATHAppendix 4C - quarterly
30/07/10	PRICE SENSITIVE	65.91KB	Share
ATHAppendix 3B and Section 708A Notice
19/07/10		123.38KB	Share
ATHPranas Research Presented at Alzheimers Disease Conference
19/07/10		75.56KB	Share
ATHNotice of General Meeting/Proxy Form
19/07/10		67.78KB	Share
ATHNew PBT2 data in 2010 Hot Topics Session
01/07/10	PRICE SENSITIVE	82.71KB	Share
ATHInvestment by Quintiles, Placement of 225 million Shares
28/06/10	PRICE SENSITIVE	31.25KB	Share
ATHReview of the Role of Metals in Alzheimers Disease
21/06/10		30.95KB	Share
ATHAppendix 3B and Section 708A Notice
08/06/10		124.66KB	Share
ATHPrana to Present Findings at American Aging Assoc Meeting
01/06/10		30.35KB	Share
ATHAppendix 4C - quarterly
30/04/10	PRICE SENSITIVE	75.25KB	Share
ATHPrana Provides Analysis of PBT2 Therapeutic Strategy for AD
29/04/10	PRICE SENSITIVE	31.44KB	Share
ATHCeasing to be a substantial holder
23/04/10		206.13KB	Share
ATHPrana to commence Phase 11b trial on PBT2
20/04/10	PRICE SENSITIVE	31.12KB	Share
ATHNew Analysis of Clinical Trial published in Journal of AD
19/04/10	PRICE SENSITIVE	42.64KB	Share
ATHChange in substantial holding
05/03/10		217.32KB	Share
TSN +ACR ADU AED AEJ AEZ AIO AJA RCM AMU ATM AVG AVX AXM AZZ ASQ BCS BLY BUL CAA CAH CBH CCP CDI PRG CIX CMV COK COZ CPL CRE CSV CTO CUV CVC CWT CXC CXM DCG DKN DLS DML DOM EAU EPX FEA FGE FML FPG FRS GDO ETM GPM GWR GXY GZL HDI NGI HGO HIG HIN HTA IDT ILF IMD IOH ITO IVA KAM KMD KRL KRM LLA MAE AEV MCE MCP MDT MEL MFG MIN 5GN GG8 MMW MRE MSF MTU MYR MYS NAN NBS NEC DTZ NGE NGF NKP NOD KZA NVT OAK OEL SYN AKE PBP ATH PME PPI PRU PTN AX1 RCI RCT VAU REF RFE RRL RXM SAR SFC SFH SFR SGN SGT SLR SNO SPL SRV SSM SUL TAM TCQ TGA TOX TPM TZL UBI UNS VIR VMG VPE VRL VTA WDS WEC WTP WYL ZSPSandP Announces March SP/ASX Index Rebalance
05/03/10		35.82KB	Share
ATHAppendix 3B and Section 708A Notice
02/03/10		107.66KB	Share
ATHCeasing to be a substantial holder
01/03/10		489.95KB	Share
ATHForm 6-K
26/02/10		98.94KB	Share
ATHAppendix 4D for the Half Year Ended 31 December 2009
25/02/10	PRICE SENSITIVE	1.04MB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change -0.001(6.67%)		Mkt cap ! $128.9M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.4¢	$89.83K	6.221M

Buyers (Bids)

No.	Vol.	Price($)
9	1895858	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	18269645	9

View Market Depth

No.	Vol.	Price($)
8	1870858	0.014
39	22189464	0.013
34	16003149	0.012
18	12494327	0.011
34	15663355	0.010

Price($)	Vol.	No.
0.015	18269645	9
0.016	4163104	13
0.017	7366424	10
0.018	12761167	22
0.019	10345967	12

Last trade - 16.10pm 11/08/2025 (20 minute delay)

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available